<DOC>
	<DOCNO>NCT02100150</DOCNO>
	<brief_summary>The purpose study determine whether NNZ-2566 safe well tolerate treatment mTBI adolescent adult .</brief_summary>
	<brief_title>A Safety Efficacy Study NNZ-2566 Patients With Mild Traumatic Brain Injury ( mTBI )</brief_title>
	<detailed_description>Traumatic brain injury ( TBI ) injury head cause external trauma lead brain cell death , inflammation , edema , hemorrhage , disruption normal brain cell function . mTBI frequently result persistent functional impairment include problem cognitive function , memory , mood , personality disorder . There currently drug available reduce brain damage sequelae result TBI . Clearly , safe effective treatment concussion injury form TBI would important development military personnel well general population . This study investigate safety tolerability treatment oral administration NNZ-2566 35 mg/kg 70 mg/kg BID adolescents adult mTBI . The study also also investigate measure efficacy treatment .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Brain Concussion</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Subject diagnosis mTBI result injury meet follow criterion : 1 . Occurred within 24 hour Screening associate clear mechanism injury alteration consciousness ( e.g. , confusion , feel daze , `` see star '' ) 2 . Was associate GCS score 1315 3 . Was associate 1 follow sign symptom , determine qualified clinician : i. Headache ii . Loss consciousness iii . Post traumatic amnesia iv . Retrograde amnesia v. Difficulty concentrate vi . Balance problem vii . Dizziness viii . Visual problem ix . Personality change x . Fatigue xi . Sensitivity light/noise xii . Numbness xiii . Nausea xiv . Vomiting d. Current symptom associate mTBI cause clinically significant impairment 2 . Subject 16 55 year old . 3 . Subject CGIS score ≥3 Screening 4 . Subject RPQ3 score ≥3 Screening 5 . Subjects take psychotropic medication must receive stable regimen ( i.e. , dosage regimen ) least 4 week prior Screening . For purpose protocol , psychotropic medication define medication prescribe intend CNS benefit . Medications headache permissible , need , accord approve prescribing information . 6 . Women childbearing potential must negative urine pregnancy test Screening . Men woman must agree use contraceptive method &lt; 1 % success rate ( e.g. , oral contraceptive , injectable progestogen , levonorgestrel implant , estrogenic vaginal ring , percutaneous contraceptive patch , intrauterine device [ IUD ] , surgical sterilization , double barrier method [ i.e. , condom diaphragm spermicidal agent ] ) . Subjects ineligible study meet follow exclusion criterion : 1 . Subject history brain surgery prior severe TBI ( base previously document GCS score ≤8 ) . 2 . Subject history seizure disorder experience seizure 24 hour precede Screening . Note : Isolated febrile seizure early childhood exclusionary . 3 . Subject history diabetes mellitus require pharmacotherapy within precede 12 month . 4 . Subject history hypothyroidism within 3 year precede Screening currently require require pharmacotherapy . 5 . Subject regularly use 1 follow psychoactive medication 4 week precede Screening : methylphenidate , dextroamphetamine , mixed amphetamine salt , amantadine , memantine , cholinesterase inhibitor , modafinil , armodafinil . 6 . Subject history substance abuse dependence , nicotine dependence , within 3 month precede Screening . 7 . Subject signs/symptoms acute impairment due alcohol use . 8 . Subject use antiepileptic medication 4 week precede Screening . 9 . Subject use bromocryptine , levodopa , ropinirole , pramipexole 4 week precede Screening . 10 . Subject history major psychiatric disorder ( include major depression , clinically significant anxiety disorder , psychotic disorder ) associate significant clinical impairment within precede 6 month . 11 . In Investigator 's opinion , subject pose current homicidal serious suicidal risk , and/or make suicide attempt within 6 month precede Screening . 12 . Subject neurological disorder mTBI ( e.g. , Parkinson 's disease , stroke , multiple sclerosis , dementia , delirium , infectious encephalopathy ) require treatment within 6 month precede Screening . 13 . Subject history , current , cerebrovascular disease . 14 . Subject history , current , malignancy . 15 . Subject unstable medical disorder may pose safety concern interfere accurate assessment safety efficacy . 16 . Subject laboratory value Screening deem clinically significant Investigator . 17 . Subject average QT interval correct use Fridericia 's formula ( QTcF ) &gt; 450 msec Screening ECG abnormality may pose potential safety concern . 18 . Subject history risk factor torsade de pointes ( e.g. , heart failure , clinically significant hypokalemia , serum potassium value Screening &lt; 3.0 mmol/L , family history long QT syndrome ) . 19 . Subject history QT/QTcF prolongation previously currently control medication , normal QT/QTcF interval could achieve medication . 20 . Subject participate another clinical treatment study within 4 week precede Screening . 21 . Subject unable provide inform consent ( deem cognitively able standard assessment ) inform consent obtain legally authorize individual ( e.g. , spouse , instance minor , parent ) . 22 . Subject pregnant nursing . 23 . Subject previously enrol study . 24 . Subject allergy strawberry .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Concussion</keyword>
</DOC>